Search
-
Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01)
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV:…
-
Hemostemix Announces Warrant Repricing and Extension
May 6, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is…
-
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
June 11, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to announce…
-
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record
May 31, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE:2VF0) (“Hemostemix” or the “Company”) reminds shareholders…
-
Hemostemix Announces the TSX Venture’s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update
May 29, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) (“Hemostemix” or the “Company”) is pleased…
-
Hemostemix to Present at the Emerging Growth Conference
May 25, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VFO.F) (“Hemostemix” or the “Company”) is…
-
Hemostemix Announces Closing of Unit Private Placement
May 10, 2021 (Source) – Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) announces it has closed its…
-
Hemostemix Announces Warrant Repricing and Extension
May 6, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is…
-
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
April 30, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased…
-
Thomas Smeenk on Hemostemix’s autologous stem cell therapy technology and why some call it ‘the fountain of youth’
In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…